Literature DB >> 18430894

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.

Yannick Arlot-Bonnemains1, Enke Baldini, Benedicte Martin, Jean-Guy Delcros, Matteo Toller, Francesco Curcio, Francesco S Ambesi-Impiombato, Massimino D'Armiento, Salvatore Ulisse.   

Abstract

Anaplastic thyroid cancers (ATC) are aggressive tumors, which exhibit cell cycle misregulations leading to uncontrolled cellular proliferation and genomic instability. They fail to respond to chemotherapeutic agents and radiation therapy, and most patients die within a few months of diagnosis. In the present study, we evaluated the in vitro effects on ATC cells of VX-680, an inhibitor of the Aurora serine/threonine kinases involved in the regulation of multiple aspects of chromosome segregation and cytokinesis. The effects of VX-680 on proliferation, apoptosis, soft agar colony formation, cell cycle, and ploidy were tested on the ATC-derived cell lines CAL-62, 8305C, 8505C, and BHT-101. Treatment of the different ATC cells with VX-680 inhibited proliferation in a time- and dose-dependent manner, with the IC50 between 25 and 150 nM. The VX-680 significantly impaired the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity showed that VX-680 induced apoptosis in the different cell lines. CAL-62 cells exposed for 12 h to VX-680 showed an accumulation of cells with > or =4N DNA content. Time-lapse analysis demonstrated that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation was abrogated following VX-680 treatment. In conclusion, our data demonstrated that VX-680 is effective in reducing cell growth of different ATC-derived cell lines and warrant further investigation to exploit its potential therapeutic value for ATC treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430894     DOI: 10.1677/ERC-08-0021

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  26 in total

1.  Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.

Authors:  Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  Endocrine       Date:  2012-04-05       Impact factor: 3.633

2.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

3.  Anaplastic thyroid cancer therapy: dream or reality?

Authors:  Rossella Elisei
Journal:  Endocrine       Date:  2012-12       Impact factor: 3.633

4.  Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.

Authors:  C M Cannon; J Pozniak; M C Scott; D Ito; B H Gorden; A J Graef; J F Modiano
Journal:  Vet Comp Oncol       Date:  2013-02-15       Impact factor: 2.613

5.  Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.

Authors:  Shih-Che Hua; Tien-Chun Chang; Hau-Ren Chen; Chieh-Hsiang Lu; Yi-Wen Liu; Shu-Hsin Chen; Hui-I Yu; Yi-Ping Chang; Ying-Ray Lee
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

Review 6.  Update on aurora kinase inhibitors in gynecologic malignancies.

Authors:  Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-11       Impact factor: 4.169

Review 7.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

Review 8.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

9.  Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Authors:  Crescent R Isham; Ayoko R Bossou; Vivian Negron; Kelly E Fisher; Rakesh Kumar; Laura Marlow; Wilma L Lingle; Robert C Smallridge; Eric J Sherman; Vera J Suman; John A Copland; Keith C Bible
Journal:  Sci Transl Med       Date:  2013-01-02       Impact factor: 17.956

10.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.

Authors:  Chiara Tuccilli; Enke Baldini; Natalie Prinzi; Stefania Morrone; Salvatore Sorrenti; Angelo Filippini; Antonio Catania; Stefania Alessandrini; Roberta Rendina; Carmela Coccaro; Massimino D'Armiento; Salvatore Ulisse
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.